

Magstim rTMS therapy

A revolutionary treatment for depression



- PROVEN TO TREAT DRUG RESISTANT MDD
- SAFE, NON INVASIVE
- FLEXIBLE FINANCE OPTIONS

www.magstim.com

magstim

Redefining the treatment of depression

As the pioneer of Transcranial Magnetic Stimulation (TMS) Technology, Magstim is recognised as a trusted supplier of diagnostic, research and therapy solutions Worldwide.

What is Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy?

Repetitive Transcranial Magnetic Stimulation (rTMS) is a form of brain stimulation that uses magnetic pulses to produce changes in neuronal activity in regions of the brain associated with mood regulation, such as the prefrontal cortex.

The treatment of rTMS therapy has gained significant clinical traction and offers a new option for patient treatment, as an effective treatment for MDD.

rTMS has the following benefits:

- An effective non-drug treatment
- Proven to treat MDD*
- Safe, non-invasive therapy
- No systemic side effects†
- One-off capital purchase – no pay per use disposables
- Built by Magstim, the pioneers of TMS

Unmet Need:

Globally, more than 350 million people of all ages suffer from depression^[1]. By the year 2030, depression is predicted to become the number one cause of disability^[2]. With traditional pharmaceutical options known to have associated side effects, clinical practitioners are increasingly turning to rTMS as a fast, effective treatment option for MDD.

Proven Efficacy without Systemic Side Effects:

In depression, over 80 separate trials and 4 separate large multicenter trials have been found to show significant improvements in depression following daily prefrontal rTMS for 3-6 weeks.

Response Rates:


A multisite, naturalistic, observational study of 307 patients, who had an average failure of 2.5 adequate medication trials, received an average of 28.3 TMS therapy sessions over an average of 42 days. This study showed that 58% of patients responded positively to TMS therapy and 37.1% of patients went into remission^[3].

Treatment procedure:

- An initial session, which includes the determination of the patient's individual stimulation level (motor threshold determination)
- 5 treatment sessions per week for approximately 3-6 weeks

Diagnosis and initial session are performed by a psychiatrist. The remaining treatment sessions are typically conducted by trained personnel.

The FDA cleared protocol for TMS Therapy treatment consists of repeated cycles of rTMS followed by rest periods (10 Hz; 4second trains; 26second wait; 75 trains for a total of 3,000 stimulations per treatment session at 120% motor threshold (37.5 min).



Comparable side effects

	Anti-depressants	ECT	rTMS
Anxiety	■	■	
Blurred vision	■		
Diarrhoea/constipation	■		
Dizziness	■	■	■ (transient)
Dry mouth	■	■	
Headache	■		■ (transient)
Insomnia/drowsiness	■	■	
Nausea	■	■	
Sexual dysfunction	■		
Weight gain	■		
Memory loss	■	■	

rTMS can be performed as an outpatient procedure with fewer side effects than traditional methods of treatment†

* In adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.

† There has been an infrequent report of seizures associated with rTMS. However, the estimated seizure risk is 0.003% of treatments, or 0.1% of patients^[3]

References:

^[1] Depression Fact Sheet (2012). World Health Organisation. ^[2] Global Burden of Disease Report (2006). Geneva, World Health Organisation

^[3] Carpenter, L et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice (2012)

Therapy chair shown for demonstration purposes

Manoeuvrability

Adjustable coil angles for optimum manoeuvrability during treatment

Mobility

Articulated coil stand designed for mobility and coil support

Comfort

Ergonomic chair designed for patient comfort throughout treatment

Variable

Motorised footswitches allow for variable seating angles

Self regulating

Magstim Air Film Coil - designed with self regulating temperature control for longer treatments

Intuitive

Magstim Rapid² Stimulator - provides reliability, simplicity and easy setup for delivering treatment protocol

Transportable

Magstim Rapid Trolley - a slim and secure solution for Magstim Stimulator transport and fixation



Learn more about why NHS clinicians are adopting rTMS as a standard of care.

www.magstim.com



Magstim Support Service:

Magstim recognises the importance of appropriate educational and technical support for health professionals working with rTMS patients. Our team of dedicated experts provide in depth training at national and regional level.

To request more information
or a quote, please visit


www.magstim.com

e-mail sales@magstim.com

or Tel +44 (0)1994 240798



Your nearest Magstim representative is:

All standard products carry the mark, comply with the Medical Device Directive 93/42/EEC, and are manufactured under a  Quality System certified to ISO 13485.

Users of Magstim Transcranial Magnetic Stimulators in the USA please note: Caution - Investigational Device.

Federal (or United States law) limits device to investigational use.

©2014 The Magstim Company Limited. Magstim®, and Air Film™ are registered trademarks of The Magstim Company Limited.

All specifications are subject to change. All marketing material is produced in good faith.

Part number 4555-00